Last reviewed · How we verify
Cultured Mesenchymal Stem Cells
Cultured mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory signaling, and differentiation into replacement cells.
Cultured mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory signaling, and differentiation into replacement cells. Used for Graft-versus-host disease (GVHD), Tissue repair and regeneration in degenerative conditions.
At a glance
| Generic name | Cultured Mesenchymal Stem Cells |
|---|---|
| Sponsor | Universidad Autonoma de Madrid |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Immunology |
| Phase | Phase 3 |
Mechanism of action
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into various cell types (osteocytes, chondrocytes, adipocytes) and secrete paracrine factors including anti-inflammatory cytokines and growth factors. These cells modulate immune responses, reduce inflammation, and promote angiogenesis and tissue remodeling at sites of injury or degeneration. The cultured MSC product leverages these properties for therapeutic benefit in degenerative and inflammatory conditions.
Approved indications
- Graft-versus-host disease (GVHD)
- Tissue repair and regeneration in degenerative conditions
Common side effects
- Infusion-related reactions
- Infection
- Immunological reactions
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee (NA)
- Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease (PHASE3)
- Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) (PHASE2)
- PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |